Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
anti-PD-1 antibody + pralsetinib + selpercatinib
- Development stage
- Preclinical
- Lead developer
- Eli Lilly
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Oral
01
Overview
This is a combination therapy consisting of an anti-PD-1 antibody (checkpoint inhibitor) plus two selective RET inhibitors (pralsetinib and selpercatinib). The anti-PD-1 component blocks the interaction between PD-1 and PD-L1, enhancing T-cell function and boosting immune response against cancer cells. Pralsetinib and selpercatinib are highly selective RET inhibitors that target RET gene rearrangements. This combination approach potentially combines immunotherapy with targeted therapy to address both immune evasion and oncogenic driver mutations in cancer treatment.
02
Targets
PDCD1 (Programmed cell death protein 1 receptor)RET (Rearranged during transfection receptor tyrosine kinase)
Beyond the preview
Go deeper on anti-PD-1 antibody + pralsetinib + selpercatinib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on anti-PD-1 antibody + pralsetinib + selpercatinib.